Researchers develop new vaccine against deadly Middle East Respiratory Syndrome

April 09, 2019

GALVESTON, Texas - A collaborative team from The University of Texas Medical Branch at Galveston, Saudi Arabia and Canada developed a potent and safe vaccine that protects against the deadly Middle East respiratory syndrome, or MERS. The findings recently were published in The Journal of Infectious Diseases.

MERS was first identified when someone died from the viral infection in 2012. The virus, which can suddenly cause severe and fatal respiratory symptoms, systemic infection and multi-organ failure, has caused more than 2,250 confirmed infections with a 35 percent mortality rate in 27 countries. MERS can be spread from camel-to-human or person-to-person. Many global cases are linked with the Arabian Peninsula because of its high camel population but it has the potential to spread globally, as seen in a 2015 outbreak in South Korea.

"In the past, we've mainly focused on developing universal influenza vaccines by targeting the viral proteins to specific cells that have a molecule called CD40 on their surfaces" said senior author Chien-Te K Tseng, professor in UTMB's Centers for Biodefense and Emerging Diseases. "We modified and optimized our earlier vaccine platform to generate new potential MERS vaccines."

Tseng said that although other research groups have investigated various MERS vaccine platforms in animal models, serious safety concerns are often associated with vaccines for the family of viruses that MERS belongs to. The current study set out to use a different vaccine platform that was safer yet still effective.

The research team made two versions of a potential vaccine and evaluated their effectiveness and safety in mice that were genetically altered to have more human-like immune responses. After the mice were vaccinated and then infected with MERS-CoV, both vaccines protected the mice against clinical signs of disease and death. However, one of the vaccines was unable to stop the virus from causing lung damage. The other potential vaccine, which more selectively targeted cells with CD40, did not result in any lung damage.

"Our platform offers a promising strategy for enhancing the safety and potency of the MERS vaccine and can also be utilized to enhance the safety and efficacy of vaccines against a broad range of pathogens," said lead author Anwar Hashem, associate professor at king Fahd Medical Research Center and Faculty of Medicine, King Abdulaziz University, Saudi Arabia.
-end-
Other authors include UTMB's Abdullah Algaissi, Anurodh Agrawal and Bi-Hung Peng, as well as Sawsan Al-amri, Rowa Alhabbab and Sayed Sohrab from King Abdulaziz University in Saudi Arabia; Abdulrahman Almasoud and Naif Khalaf Alharbi from King Abdullah International Medical Research Center in Saudi Arabia and Marsha Russell and Xuguang Li from Health Canada.

University of Texas Medical Branch at Galveston

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.